VentriPoint Diagnostics Ltd.
TSX VENTURE : VPT
PINK SHEETS : VPTDF

VentriPoint Diagnostics Ltd.

May 18, 2011 15:35 ET

VentriPoint to Exhibit at 45th Annual Meeting of the Association of European Paediatric Cardiologists

VMS™ Heart Analysis System Also Featured in Two Clinical Studies

SEATTLE, WASHINGTON--(Marketwire - May 18, 2011) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) will be exhibiting its VMS™ heart analysis system at the Annual Meeting of the Association of European Paediatric Cardiologists (AEPC) from May 18th to May 21stin Granada, Spain. VentriPoint is initially focusing its technology on quantifying 2D imagesof the right ventricle (RV). Using 2D ultrasound images, the VMS™ performs knowledge-based reconstruction to create 3D images of the right ventricle and calculates accurate volumetric and functional measurements. Clinical studies have shown that these VMS™ measurements are equivalent to those using Magnetic Resonance Imaging (MRI), the current standard of care. VentriPoint's booth is number 19.

"It is a sign of significant progress for VentriPoint to have the VMS™ heart analysis system exhibited for the first time at a major heart conference," said Dr. George Adams, President and CEO of VentriPoint, "The initial VMS™ installations have been exceptionally smoothand the product has proven to be ready to show commercially. The AEPC is a good conference to demonstratethe VMS™ to a focused group of paediatric cardiologists, who recognize the need for better and more efficient RV imaging and analysis."

In addition, two papers will be presented on clinical studies using the VMS™.

  1. "Assessment of Standard and Non-Standard Echocardiographic Acoustic Windows to Visualize the Right Ventricle in Tetralogy of Fallot" by M-P. Waiss (VentriPoint Inc.), L. Mertens (Hospital for Sick Children, Toronto) and S. Ge (St. Christopher's Children's Hospital, Philadelphia). The study used the unique ability of the VMS™ to simultaneously show the 2D plane within the 3D reconstruction to overcome a lack of visualization of the RV using standard techniques in patients with blue-baby syndrome.
  1. "Echocardiographic Assessment of Right Ventricular Volumes: A Comparison of Different Techniques in Children after Surgical Repair for Tetralogy of Fallot."by Dragulescuet al(Hospital for Sick Children, Toronto). This study showed that the use of 2D ultrasound with VMS™ provided critical RV function measurementsthat were equivalent to MRI based measurements.

About the Association of European Paediatric Cardiologists (AEPC)

Growing at an annual rate of 11%, the 2010 overall membership of the AEPC was 1,060 paediatric cardiologists and other specialists working in the field of paediatric cardiology and its related disciplines. This positions the Association as the largest democratically administered global association in the field of congenital cardiology with a membership that now represents all the continents. The mission of AEPC is to promote (a) the knowledge of the normal and diseased heart and circulation (b) the exchange of knowledge amongst the global experts, (c) continuous education and (d) harmonizing the training of paediatric cardiology and related disciplines.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and it is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Contact Information